Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NV-5138 · SPN820

Small molecule · Modulator of mTORC1 · developed by Navitor Pharmaceuticals

Phase 2 Most advanced trial (none active)
1 Registered trials

What is NV-5138?

NV-5138 is an orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling. It is being studied in treatment-resistant depression.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SPN820
Drug type
Small molecule
Targets
mTORC1
Mechanism
Modulator of mTORC1
Pathways
mTORC1 signaling
Therapy area
Psychiatry
Developer
Navitor Pharmaceuticals, Inc.
In trials of
SUPN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
06CA9QMG6Z

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05066672 Phase 2 Treatment Resistant Depression Completed SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Treatment Resistant Depression

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.